Cognition Therapeutics' Phase 2 START Study exceeds 50% enrollment for testing zervimesine in early Alzheimer's disease.
Quiver AI Summary
Cognition Therapeutics, Inc. announced that its Phase 2 START Study, aimed at evaluating zervimesine (CT1812) for treating early Alzheimer’s disease, has surpassed 50% enrollment, with support from an $81 million grant by the National Institute of Aging. The study, conducted in collaboration with the Alzheimer’s Clinical Trials Consortium, seeks to enroll 540 participants to assess cognition and safety over 18 months. Dr. Christopher van Dyck emphasized the commitment from investigators and the interest from participants in this innovative treatment. Initial findings from a related Phase 2 study showed promising results, with zervimesine slowing cognitive decline, particularly in patients with lower protein levels associated with Alzheimer’s. Cognitive Therapeutics aims to create effective treatments for neurodegenerative diseases by targeting specific mechanisms underlying these disorders.
Potential Positives
- Phase 2 START Study surpassing 50% enrollment indicates strong participant interest and support, which is crucial for the study's success.
- Significant grant support of $81 million from the National Institute of Aging underscores the credibility and potential impact of the research being conducted.
- Previous Phase 2 SHINE Study results demonstrating a 38% slowing of cognitive decline with zervimesine treatment builds confidence in the drug's efficacy.
- The adoption of zervimesine as the United States Adopted Name (USAN) indicates regulatory acceptance and a step forward in its development for market readiness.
Potential Negatives
- The press release highlights the Phase 2 START Study but does not provide detailed information on the overall success or effectiveness of zervimesine beyond initial findings, which may raise concerns about the drug's efficacy in later stages.
- The understanding that zervimesine's potential effectiveness may vary significantly based on specific biomarkers (like p-tau217) could indicate a limited market or treatment applicability, potentially impacting the company’s growth prospects.
- The emphasis on ongoing clinical trials and the comprehensive list of risks associated with forward-looking statements may signal to investors uncertainties about the company's future performance and product viability.
FAQ
What is the START Study by Cognition Therapeutics?
The START Study is a Phase 2 trial evaluating the efficacy of zervimesine for early Alzheimer's disease in 540 participants.
How much enrollment has the START Study reached?
The START Study has surpassed 50% enrollment, indicating strong participation and interest in the investigation.
What is zervimesine (CT1812)?
Zervimesine is an investigational oral medication aimed at treating neurodegenerative disorders like Alzheimer's and dementia with Lewy bodies.
Who supports the START Study financially?
The study receives $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health.
What are the expected outcomes of the START Study?
The study aims to evaluate the effectiveness and tolerability of zervimesine in slowing cognitive decline in early Alzheimer's patients.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CGTX Insider Trading Activity
$CGTX insiders have traded $CGTX stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CGTX stock by insiders over the last 6 months:
- LISA RICCIARDI (CEO & President) purchased 38,851 shares for an estimated $30,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CGTX Hedge Fund Activity
We have seen 24 institutional investors add shares of $CGTX stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ACADIAN ASSET MANAGEMENT LLC added 897,353 shares (+814.1%) to their portfolio in Q1 2025, for an estimated $377,606
- VOSS CAPITAL, LP added 500,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $350,650
- ALYESKA INVESTMENT GROUP, L.P. removed 500,000 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $210,400
- CM MANAGEMENT, LLC added 200,000 shares (+100.0%) to their portfolio in Q1 2025, for an estimated $84,160
- VIRTU FINANCIAL LLC removed 80,180 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $33,739
- VANGUARD PERSONALIZED INDEXING MANAGEMENT, LLC added 56,002 shares (+inf%) to their portfolio in Q1 2025, for an estimated $23,565
- TEXAS CAPITAL BANK WEALTH MANAGEMENT SERVICES INC removed 55,395 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $38,848
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
PURCHASE, N.Y., July 01, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced that the Phase 2 ‘START’ Study surpasses 50% enrollment. The START Study is being conducted with partners at the Alzheimer’s Clinical Trials Consortium (ACTC), with $81 million in grant support from the National Institute of Aging (NIA) at the National Institutes of Health.
Christopher van Dyck, MD, stated, “This is an important milestone for the study and is a testament to the commitment of the investigators and site teams and a high level of interest from participants in an oral treatment with a novel approach to addressing amyloid in early Alzheimer’s disease.” Dr. Van Dyck is the director of the Yale Alzheimer’s Disease Research Unit and the Yale Alzheimer’s Disease Research Center. He also serves as a member of the ACTC executive committee and is the project director of the START Study.
The START Study ( NCT05531656 ) is designed to enroll up to 540 individuals with mild Alzheimer’s disease who will be treated with zervimesine (CT1812) or placebo for 18 months. Participants are being enrolled at approximately 50 sites in the United States, including premier institutions in the ACTC network. More information about this study may found at https://start-study.org .
“Participants in the START Study are just beginning to show signs of cognitive loss,” stated Anthony O. Caggiano, MD, PhD , Cognition’s CMO and head of R&D. “Based on our experience from the Phase 2 ‘SHINE’ Study in mild-to-moderate Alzheimer’s disease, we expect that patients with less disease pathology may experience the most benefit from zervimesine treatment. We look forward to working with our colleagues at ACTC to understand more about zervimesine’s potential in patients across the spectrum of Alzheimer’s disease.”
In the Phase 2 SHINE Study ( NCT03507790 ), once-daily oral zervimesine treatment slowed cognitive decline by 38% compared to placebo. Participants with lower levels of the protein, p-tau217 in their blood plasma had a more robust treatment response, experienced a 95% slowing of their cognitive decline. Lower levels of p-tau217 may identify people who have not yet sustained severe neuronal loss, offering them a greater potential for treatment response.
About Zervimesine (CT1812)
Zervimesine (CT1812) is an investigational, oral, once-daily pill in development for the treatment of CNS diseases such as Alzheimer’s disease and dementia with Lewy bodies (DLB). While these diseases have different symptoms, both are associated with the buildup of certain proteins in the brain – Aβ and ɑ-synuclein. As these proteins bind to neurons, they can damage and ultimately destroy the neurons. This results in a progressive loss in a person’s ability to learn, recall memories, move efficiently, or communicate. These diseases progress relentlessly and ultimately result in death. If zervimesine can interrupt the toxic effects of these proteins, it may be able to slow progression of disease and improve the lives of those suffering from Alzheimer’s and DLB. Zervimesine has been generally well tolerated in clinical studies to date.
The USAN Council has adopted zervimesine as the United States Adopted Name (USAN) for CT1812.
About the START Study
The START study will measure the efficacy and tolerability of once-daily oral CT1812 in individuals with mild cognitive impairment or early Alzheimer’s disease (MMSE 20-30) who have elevated Aβ (as measured by PET or CSF). Participants will be randomized to receive CT1812 or placebo for 18 months. The study will assess cognition and executive function using validated tools including the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) and ADAS-Cog rating scales, as well as biomarker and safety findings.
The START study is supported by a grant from the National Institute of Aging (NIA) at the National Institutes of Health (R01AG065248). The study is being conducted in collaboration with the Alzheimer’s Clinical Trials Consortium (ACTC), an NIA-funded (grant number U24AG057437) clinical trial network of 35 leading academic sites with expertise in clinical trials in Alzheimer’s disease.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc.
, is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system. We recently completed Phase 2 studies of our lead candidate, zervimesine (CT1812) in dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease and geographic atrophy secondary to dry AMD. The Phase 2 START study (
NCT05531656
) in early Alzheimer’s disease is ongoing. We believe zervimesine can regulate pathways that are impaired in these diseases though its interaction with the sigma-2 receptor, a mechanism that is functionally distinct from other approaches for the treatment of degenerative diseases. More about Cognition Therapeutics and our pipeline can be found at
https://cogrx.com
.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release or made during the conference, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including zervimesine (CT1812), and any expected or implied benefits or results, including that initial clinical results observed with respect to zervimesine will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of zervimesine, any analyses of the results therefrom and our expectations regarding the enrollment of patients in in our START study, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; the impacts of ongoing global and regional conflicts on our business, supply chain and labor force; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at
www.sec.gov
. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contact Information:
Cognition Therapeutics, Inc. [email protected] |
Casey McDonald (media)
Tiberend Strategic Advisors, Inc. [email protected] |
Mike Moyer (investors)
LifeSci Advisors [email protected] |
This press release was published by a CLEAR® Verified individual.